CONTRACT NO: DAMD17-93-C-3004

TITLE: PRECLINICAL PHARMACODYNAMIC AND PHARACOKINETIC STUDIES OF INVESTIGATIONAL NEW DRUGS

PRINCIPAL INVESTIGATOR: Dr. Patricia Noker

CONTRACTING ORGANIZATION: Southern Research Institute
2000 Ninth Avenue South
P.O. Box 55305
Birmingham, Alabama 35255-5305

REPORT DATE: November 11, 1993

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command, Fort Detrick
Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs

Dr. Patricia Noker

Southern Research Institute
2000 Ninth Avenue South
P.O. Box 55305
Birmingham, Alabama 35255-5305

Approved for public release; distribution unlimited

Pharmacokinetics, Drugs, lab animals, RAD I, V

Unclassified

Unclassified
LTC Moshe Shmuklarsky, M.D.
Walter Reed Army Institute of Research
ATTN: SGRD-UWM-C
Forest Glen Annex
Washington, D.C.

Reference: Contract No.: DAMD17-93-C-3004
Subject: Annual Report
Contractor: Southern Research Institute
Principal Investigator: Dr. Patricia E. Noker
Telephone No.: (205) 581-2335
SRI Report No.: SRI-BIO-93-941

Dear Dr. Shmuklarsky:

The following is a listing of the activities performed under this contract during the above referenced contract year:

1. Under Task Order 92-01, a protocol and a cost estimate for the performance of a pharmacokinetic and metabolism study of sodium artelinate (WR255663) in rats were prepared and submitted to the COR. This study was, however, postponed for an unspecified period of time due to lack of appropriate funding.

2. Task Order 93-02, which entails the performance, in dogs, of a pharmacokinetic, bioavailability and metabolism study of WR242511, an agent proposed as a cyanide pretreatment/prophylactic drug, was issued. Validation of the analytical methods to be used during the study was initiated in October. To date, no reportable data are available.

3. Under Task Order 93-03, a protocol was prepared for the performance, in dogs, of a pharmacokinetic and metabolism
Southern Research Institute

LTC Moshe Shmuklarsky
Walter Reed Institute

study of HI-6 (WR249655), a compound which is under consideration as a nerve agent antidote. A request for a cost estimate for the performance of this study is pending.

Sincerely,

Patricia E. Noker, Ph.D.
Head, Biochemical Pharmacology

Approved by:

Donald L. Hill, Ph.D.
Director, Biochemistry Research